Article Details
Retrieved on: 2021-02-12 15:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The ACTIV-2 trial will continue to evaluate monoclonal antibodies and other small molecules for outpatient COVID treatment. Camostat is the first ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here